AmberGen receives US Patent 8,148,062 for detecting disease causing genetic mutations such as breast and colorectal cancer using affinity tags in translated nascent proteins

AmberGen awarded 3-year Phase II SBIR grant for discovery of tumor autoantigen biomarkers using Bead-AMS™ proteomic array technology